Mizuho Lowers Abbott Laboratories (NYSE:ABT) Price Target to $115.00

Abbott Laboratories (NYSE:ABT) had its target price decreased by Mizuho from $125.00 to $115.00 in a note issued to investors on Friday,MarketScreener reports. The firm presently has a “neutral” rating on the healthcare product maker’s stock. Mizuho’s target price would indicate a potential upside of 18.69% from the stock’s current price.

Several other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Leerink Partners lowered their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Stifel Nicolaus reduced their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday. Finally, Sanford C. Bernstein decreased their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $121.00.

Abbott Laboratories Price Performance

NYSE:ABT opened at $96.89 on Friday. The stock has a market capitalization of $168.75 billion, a PE ratio of 27.14, a P/E/G ratio of 1.57 and a beta of 0.79. Abbott Laboratories has a 1-year low of $93.92 and a 1-year high of $139.06. The firm has a fifty day simple moving average of $107.89 and a 200 day simple moving average of $118.65. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter last year, the company posted $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. 0.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Trust Co boosted its stake in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after buying an additional 15,394 shares during the period. Danica Pension Livsforsikringsaktieselskab bought a new position in Abbott Laboratories during the 3rd quarter worth $185,640,000. Asset Management One Co. Ltd. raised its holdings in Abbott Laboratories by 2.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after acquiring an additional 19,966 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares during the period. Finally, AE Wealth Management LLC lifted its position in shares of Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after acquiring an additional 11,264 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.